Skip to main content

Case Studies

Reduce risk. Improve confidence. Advance your drug programme with human-relevant data.

Drug development is filled with uncertainty. Promising therapies can fail because traditional preclinical models don't always predict how patients will respond. At REPROCELL, we help pharmaceutical and biotechnology teams generate translational human data earlier in development, enabling better decisions before critical clinical and regulatory milestones.

The case studies below show how organisations have used our human tissue and translational research capabilities to de-risk development programmes, investigate safety concerns, demonstrate target engagement, support regulatory submissions, and move promising therapies closer to patients.

If you don't see an example that matches your therapeutic area, contact our team to discuss similar studies and available human tissue models.

IPM
Lindsey and Amna at microscopes

Achieve regulatory approval

When IPM approached the regulators for approval of their HIV prevention ring, they requested additional data on uterine contractility. Find out how our studies in fresh human uterine tissue helped IPM gain approval.
Amgen
skin biopsies

Avoid species differences

Read our case study on Amgen's publication, which highlights the useful comparisons that can be made between matched tissues from preclinical species and humans.
Roche
KarenM pipetting at wire myographs

Eliminate clinical adverse effects

Adverse effects may go undetected during preclinical safety assessments and only become apparent during clinical trials. In most cases, such adverse effects in humans were not observed in animal models.
Bionorica
Michael at wire myographs

Validate therapeutic potential

REPROCELL supported Bionorica in advancing BNO 1095, a plant-based treatment for primary dysmenorrhea, through human tissue studies demonstrating its spasmolytic effects.
GI Health Pharma
intestinal-motility

Prove human efficacy

This study demonstrates that GC-C agonists activate cGMP-dependent signalling in human intestinal tissue, regulating ion transport to promote fluid secretion and helping explain their therapeutic effects in gastrointestinal disorders.
NeurAxon
Wire myograph drawing

De-risk cardiovascular safety

A selective nNOS inhibitor was evaluated in human resistance arteries and demonstrated no adverse effects on vascular contractility or vasoreactivity, providing strong evidence of a favourable vascular safety profile and supporting its continued development.
CV Therapy Pharma
Coronary arteries assay

Identify clinical safety signals

Using isolated human cardiac and vascular tissues, REPROCELL demonstrated the direct effects of vernakalant and flecainide on contractility and vascular tone, providing mechanistic insight into their haemodynamic effects.
Equillium
undefined-Jul-10-2026-03-37-44-6921-PM

Confirm human target engagement

Using human-derived intestinal tissues, REPROCELL demonstrated robust target engagement of an AhR modulator, providing translational evidence of pathway activation and supporting progression into clinical development.
Axikin
Multiple human lung parenchymal 3-5mm3 explants dissected from diseased COPD lung tissue

Strengthen target engagement

Using native human lung tissue, REPROCELL demonstrated that CCR3 directly regulates airway smooth muscle contractility, providing mechanistic evidence to support the development of novel asthma therapies.
Arcede Pharma
03AUG20 Woman with inhaler athsma-1

De-risk clinical progression

REPROCELL helped an anonymised pharmaceutical company de-risk a novel respiratory therapy by generating clinically relevant data from human lung tissue models.

Contact our experts